The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the ...

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ...

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...